AI interpretation based on checked source excerpts. Issuer assertions and evidence limitations remain explicit.
Policy quality-scores-3: six equally weighted categories. The overall score requires full coverage. Missing inputs are not zero. Qualitative grades are sourced interpretations, not probabilities. 6/6 · 29/10/2026
Moat50
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
structural advantage · 2/4 · Minimum purchase commitments and cancellation restrictions demonstrate some contractual protection. Broad bioprocessing workflow coverage provides relevant operating context, but does not prove customer dependence or superior alternatives. Evidence supports a bounded advantage while leaving portfolio-wide technical switching costs and competitive differentiation unresolved.
durability · 2/4 · Approximately $5.2 billion of remaining performance obligations at December 31, 2025 spans multiple years, demonstrating commercial continuity beyond annual purchases. The balance includes warranties and services, however, and does not establish renewal protection. Realized trade-name impairment also cautions against assuming lasting intangible value.
customer dependency · 2/4 · Assessed indirectly from minimum consumables commitments and increased Biotechnology and Life Sciences consumables sales through September 2026. These demonstrate repeat demand and some purchasing obligations. Earlier declines at two large customers show variability; no renewal rate, qualification barrier or inability to switch is established.
erosion resilience · 2/4 · Consumables growth provides evidence of resilience, but Diagnostics price reductions and realized intangible and facility impairments show limits. These are observed outcomes, unlike generic competitive risks. The mixed record does not establish durable protection against procurement pressure or technology changes, nor does it demonstrate broad competitive failure.
Pricing power44
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
realized pricing · 2/4 · Pricing outcomes are mixed. Biotechnology pricing contributed 1.0% to nine-month 2026 sales growth but insignificantly in the quarter. Life Sciences contributed 0.5% quarterly and insignificantly year to date. Diagnostics prices declined 1.0% quarterly and 1.5% year to date, reflecting procurement, reimbursement changes and promotions.
retention · 2/4 · Retention is assessed indirectly from noncancelable orders, long-term minimum purchases and increased consumables sales. These support repeat business and contractual continuity, while prior customer-specific purchasing declines temper the assessment. Neither aggregate demand growth nor remaining obligations supplies a measured customer retention or renewal rate.
margin resilience · 2/4 · Diagnostics' third-quarter 2026 operating margin declined 570 basis points. Acquired-business dilution and inventory fair-value accounting were substantial unfavorable contributors, while core sales and tariff refunds provided an offset. This establishes mixed resilience in an important segment; it neither isolates a pricing-driven decline nor demonstrates strong portfolio-wide margin protection.
contractual freedom · 1/4 · Centralized purchasing and competitive bidding constrain pricing discretion, reinforced by actual Diagnostics price reductions from procurement, reimbursement changes and promotions. Minimum purchase commitments protect some demand but do not establish unilateral repricing rights. The weak grade applies to evidenced constraints; broader escalation and renewal terms are unavailable.
Predictability82
5 consecutive published annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.
- Nondeclining revenue years (%)
- 50.00
- Revenue growth volatility (pp)
- 12.08
- Positive FCF years (%)
- 100.00
- FCF margin volatility (pp)
- 1.07
- observedAnnualPeriods
- 5.00
Financial strength74
Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or reported pretax profit plus reported gross interest expense. Reported EBIT is distinct from GAAP operating income and gross interest. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.
- debtFcfGrade
- 64.26
- netDebtEbitGrade
- 41.14
- interestCoverageGrade
- 100.00
- currentRatioGrade
- 89.92
- Debt / FCF (x)
- 3.50
- Net debt / operating income (x)
- 2.94
- Interest coverage (x)
- 17.70
- Current ratio (x)
- 1.87
Capital allocation83
Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or EBIT calculated from reported pretax profit plus reported gross interest expense; the issuer-reported EBIT is distinct from GAAP operating income and gross interest; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. ROIC remains undefined for nonpositive invested capital; the explicit asset-return alternative does not change the ROIC chart. Missing financial inputs alone never trigger an alternative. Does not establish acquisition quality or buyback timing.
- 3-year pre-tax operating return (%)
- 7.58
- 3-year average dilution (%)
- -4.40
- 3-year average SBC / revenue (%)
- 1.23
- cashConversionGrade
- 100.00
Management56
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
capital discipline · 2/4 · Nine-month 2026 continuing-operations operating cash flow of $4.742 billion supported $761 million of capital expenditure and $3.982 billion of non-GAAP free cash flow. Acquisition payments of $9.881 billion exceeded operating cash generation. Realized trade-name and facility impairments temper the positive cash-generation evidence; acquisition returns remain unproven.
incentive alignment · 3/4 · Implemented multiyear vesting, a three-year PSU performance period followed by two-year holding, actual year-end ownership compliance and an adopted clawback demonstrate strong alignment mechanisms. Founder RSUs were subsequently waived; that waiver does not cancel the separately disclosed options. These mechanisms do not establish realized incentive effectiveness.
execution · 2/4 · Assessed indirectly from third-quarter 2026 core revenue growth of 3.0%, increased consumables demand and higher nine-month operating cash generation. Impairments and Diagnostics margin weakness make execution mixed. Core growth now excludes customer tariff refunds. These results precede the new CEO's October 1 effective appointment and cannot demonstrate her subsequent execution.
governance · 2/4 · The lead independent director actually exercises meeting authority, and shareholders approved the amended incentive plan in May 2026. These establish functioning oversight and approval mechanisms. The chairman is non-independent, and the supplied passages do not establish broader oversight effectiveness or an exceptional governance record.
Evidence
Remaining performance obligations include noncancelable purchase orders, the non-lease portion of minimum purchase commitments under long-term consumable supply arrangements, extended warranty and service and other long-term contracts.
2025 Form 10-K, revenue note: types of remaining performance obligations · Filed 24/02/2026
While the remaining performance obligation disclosure is similar in concept to backlog, the definition of remaining performance obligations excludes leases and contracts that provide the customer with the right to cancel or terminate for convenience with no substantial penalty, even if historical experience indicates the likelihood of cancellation or termination is remote.
2025 Form 10-K, revenue note: cancellation and lease exclusions · Filed 24/02/2026
As of December 31, 2025, the aggregate amount of the transaction price allocated to remaining performance obligations was approximately $5.2 billion.
2025 Form 10-K, revenue note: remaining performance obligations at December 31, 2025 · Filed 24/02/2026
The Company expects to recognize revenue on approximately 47% of the remaining performance obligations over the next 12 months, 26% over the subsequent 12 months, and the remainder recognized thereafter.
2025 Form 10-K, revenue note: expected recognition schedule · Filed 24/02/2026
The bioprocessing business’ offering includes cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish, as well as single-use hardware and consumables and services such as the design and installation of full manufacturing suites.
2025 Form 10-K, Biotechnology business: bioprocessing workflow offering · Filed 24/02/2026
The year-over-year increase in total segment core sales in the nine-month period ended September 25, 2026 was led by increased sales of consumables, partially offset by lower equipment sales.
Third-quarter 2026 Form 10-Q, Biotechnology: nine-month consumables and equipment demand · Filed 21/10/2026
The year-over-year increase in total segment core sales in both the three and nine-month periods ended September 25, 2026 was driven by an increase in consumables sales, and to a lesser extent higher demand for equipment.
Third-quarter 2026 Form 10-Q, Life Sciences: three- and nine-month demand · Filed 21/10/2026
41
Table of Contents
The year-over-year decrease in segment core sales was led by the life science consumables business, primarily in North America, driven by lower demand for the plasmids and mRNA product lines at two large customers and lower funding levels at emerging biotechnology and academic research customers.
2025 Form 10-K, Life Sciences: customer-specific and funding-related demand declines · Filed 24/02/2026
Core sales growth excluding respiratory testing (non-GAAP)
7.0
%
5.0
%
Price decreases in the segment of 1.0% and 1.5%, respectively, in the three and nine-month periods ended September 25, 2026 were primarily attributable to the impact of China’s volume-based procurement program and reimbursement changes, as well as the impact of sales promotions and are reflected as a component of core sales above.
Third-quarter 2026 Form 10-Q, Diagnostics: realized price decreases and causes · Filed 21/10/2026
Comparable 2025 Period
Total sales growth (GAAP)
0.5
%
5.0
%
Impact of:
Currency exchange rates
0.5
%
(1.5)
%
Tariff refunds to customers
4.0
%
1.0
%
Core sales growth (non-GAAP)
5.0
%
4.5
%
Price increases in the segment did not have a significant impact on sales growth during the three-month period ended September 25, 2026 and contributed 1.0% to sales growth on a year-over-year basis during the nine-month period ended September 25, 2026 and are reflected as a component of core sales above.
Third-quarter 2026 Form 10-Q, Biotechnology: growth reconciliation and pricing contribution · Filed 21/10/2026
Comparable 2025 Period
Total sales growth (GAAP)
4.0
%
4.5
%
Impact of:
Currency exchange rates
0.5
%
(1.0)
%
Core sales growth (non-GAAP)
4.5
%
3.5
%
Price increases in the segment contributed 0.5% to sales growth on a year-over-year basis during the three-month period ended September 25, 2026 and are reflected as a component of core sales above.
Third-quarter 2026 Form 10-Q, Life Sciences: growth reconciliation and quarterly pricing contribution · Filed 21/10/2026
Price changes did not have a significant impact on sales growth during the nine-month period.
Third-quarter 2026 Form 10-Q, Life Sciences: nine-month pricing impact · Filed 21/10/2026
•Governmental and private healthcare providers and payors around the world are increasingly utilizing managed care for the delivery of healthcare services, centralizing purchasing, limiting the number of vendors that may participate in purchasing programs, forming group purchasing organizations, strategic alliances and integrated health delivery networks and pursuing consolidation to improve their purchasing leverage, using competitive bid processes to procure healthcare products and services and investing in healthcare practices to increase their control over healthcare spending.
2025 Form 10-K, risk factors: centralized purchasing and competitive bidding · Filed 24/02/2026
Operating Profit Performance
Operating profit margin decreased 570 basis points during the three-month period ended September 25, 2026 as compared to the comparable period of 2025.
Third-quarter 2026 Form 10-Q, Diagnostics: operating margin decline · Filed 21/10/2026
•Incremental dilutive effect in 2026 of acquired businesses - 365 basis points
Third-quarter 2026 Form 10-Q, Diagnostics: acquired-business margin dilution · Filed 21/10/2026
•Third quarter 2026 acquisition-related fair value adjustment to inventory related to the Masimo Acquisition - 295 basis points
Third-quarter 2026 Form 10-Q, Diagnostics: acquisition inventory adjustment · Filed 21/10/2026
•Higher third quarter 2026 core sales and the impact of IEEPA tariff refunds, net of the impact of product mix and changes in leverage in the segment’s operational and administrative cost structure - 30 basis points
Third-quarter 2026 Form 10-Q, Diagnostics: favorable operating margin contributors · Filed 21/10/2026
The Company recorded a noncash impairment charge of $432 million pretax ($328 million after-tax) related to the trade name for the nine-month period ended September 26, 2025, which is included in SG&A expenses in the accompanying Consolidated Condensed Statement of Earnings.
Third-quarter 2026 Form 10-Q, intangible assets: 2025 trade-name impairment · Filed 21/10/2026
The amount of the impairment was primarily attributable to the conclusion that the trade name was no longer indefinite-lived, as well as current lower levels of demand in the genomics market, including at emerging biotechnology customers and at two large customers.
Third-quarter 2026 Form 10-Q, intangible assets: impairment causes · Filed 21/10/2026
Additionally, during the three and nine-month periods ended September 25, 2026, the Company recorded a $52 million impairment related to a facility in the Biotechnology segment and in the nine-month period ended September 26, 2025, the Company recorded a $15 million impairment related to another facility in the Biotechnology segment, which were both recorded in cost of sales in the accompanying Consolidated Condensed Statements of Earnings.
Third-quarter 2026 Form 10-Q, asset impairments: Biotechnology facilities · Filed 21/10/2026
Cash Flow from Continuing Operations, Free Cash Flow from Continuing Operations and Related Measures
($ in millions)
Three-Month Period Ended
Year-over-Year Change
Nine-Month Period Ended
Year-over-Year Change
September 25, 2026
September 26, 2025
September 25, 2026
September 26, 2025
Total Cash Flow from Continuing Operations:
Third-quarter 2026 earnings release, cash-flow reconciliation: units, periods and continuing-operations scope · Filed 21/10/2026
Net cash provided by operating activities from continuing operations (GAAP)
$
1,886
$
1,662
~ 13.5
%
$
4,742
$
4,299
~ 10.5
%
Less: payments for additions to property, plant & equipment (capital expenditures) (GAAP)
(255)
(292)
(761)
(785)
Plus: proceeds from sales of property, plant & equipment (capital disposals) (GAAP)
1
—
1
10
Free cash flow from continuing operations (non-GAAP)
$
1,632
$
1,370
~ 19.0
%
$
3,982
$
3,524
~ 13.0
%
Operating Cash Flow from Continuing Operations to Net Earnings from Continuing Operations Conversion Ratio:
Third-quarter 2026 earnings release, cash-flow reconciliation: operating cash, capital expenditure and non-GAAP free cash flow · Filed 21/10/2026
Less: earnings from discontinued operations, net of income taxes
(28)
—
Net earnings from continuing operations
3,106
2,417
Noncash items:
Depreciation
597
555
Amortization of intangible assets
1,410
1,269
Amortization of acquisition-related inventory fair value step-up
130
—
Stock-based compensation expense
266
235
Investment losses and pretax gain on sale of product line
97
140
Impairment charges
52
548
Change in trade accounts receivable, net
(23)
(65)
Change in inventories
(229)
(242)
Change in trade accounts payable
(160)
(134)
Change in prepaid expenses and other assets
37
(53)
Change in accrued expenses and other liabilities
(541)
(371)
Net cash provided by operating activities from continuing operations
4,742
4,299
Cash flows from investing activities:
Cash paid for acquisitions
(9,881)
—
Payments for additions to property, plant and equipment
(761)
(785)
Proceeds from sales of property, plant and equipment
1
10
Payments for purchases of investments
(86)
(79)
Proceeds from sales of investments
—
12
Proceeds from sale of product line
—
9
All other investing activities
31
21
Total cash used in investing activities for continuing operations
(10,696)
(812)
Cash flows from financing activities:
Third-quarter 2026 Form 10-Q, cash-flow statement: nine-month continuing-operations operating and investing activities, dollars in millions · Filed 21/10/2026
As a result, the Committee regularly reviews external executive compensation practices and trends and incorporated best practices into our 2025 executive compensation program:
What We Do
What We Don't Do
Multi-year vesting requirement for stock options, and three-year performance period plus further two-year holding period for Performance Stock Units ("PSUs")
March 25, 2026 proxy, compensation governance: implemented 2025 vesting and holding requirements · Filed 25/03/2026
Each NEO employed by Danaher as of December 31, 2025, was in compliance with the stock ownership requirements as of such date.
March 25, 2026 proxy, stock ownership: actual compliance at December 31, 2025 · Filed 25/03/2026
This policy provides for recovery of incentive-based compensation erroneously received by current or former executive officers during the three completed fiscal years immediately preceding the year in which the Company is required to prepare an accounting restatement due to material noncompliance with financial reporting requirements.
March 25, 2026 proxy, adopted restatement clawback: recovery scope · Filed 25/03/2026
Lead Independent Director
Because our Chairman is not independent within the meaning of the New York Stock Exchange ("NYSE") listing standards, our Corporate Governance Guidelines require the appointment of a “Lead Independent Director” and our independent directors have appointed Ms.
March 25, 2026 proxy, Board leadership: non-independent chairman and required lead independent director · Filed 25/03/2026
Ms. Filler has exercised this authority by typically requiring meetings of the non-management directors at the end of regularly scheduled Board meetings.
March 25, 2026 proxy, Board leadership: exercise of independent-director meeting authority · Filed 25/03/2026
On May 5, 2026, at the annual meeting of shareholders (the “Annual Meeting”) of Danaher Corporation (the “Company”), as further described in Item 5.07 below, the Company’s shareholders approved the Amended and Restated Danaher Corporation Omnibus Incentive Plan (the “Plan”).
May 7, 2026 Form 8-K: shareholder approval of amended incentive plan on May 5, 2026 · Filed 07/05/2026
•Non-GAAP core revenue excluding respiratory revenue increased 5.5% year-over-year and non-GAAP core revenue increased 3.0% year-over-year.
Third-quarter 2026 earnings release: reported non-GAAP core revenue growth · Filed 21/10/2026
•With respect to core sales and core sales excluding respiratory testing, (1) we exclude the impact of currency translation because it is not under management’s control, is subject to volatility and can obscure underlying business trends, (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult and (3) beginning with the Company’s Quarterly Report on Form 10-Q in the third quarter of 2026, we exclude tariff refunds to customers to help customers better understand underlying growth trends in the Company’s business that otherwise may be obscured by such item.
Third-quarter 2026 earnings release: core-sales exclusions, including newly excluded customer tariff refunds · Filed 21/10/2026
On August 3, 2026, Danaher Corporation (the “Company” or “Danaher”) announced that, effective as of October 1, 2026 (the “Effective Date”), the Board of Directors of the Company (the “Board”) has appointed Julie Sawyer Montgomery as President and Chief Executive Officer of the Company (the “CEO”).
August 3, 2026 Form 8-K: CEO appointment effective October 1, 2026 · Filed 03/08/2026
The Company operates in a highly competitive business environment in most markets, and the Company’s long-term growth and profitability will depend in particular on its ability to expand its business in high-growth geographies and high-growth market segments, identify, consummate and integrate appropriate acquisitions and identify and consummate appropriate investments and strategic partnerships, develop innovative and differentiated new products and services with higher gross profit margins, expand and improve the effectiveness of the Company’s sales force, continue to reduce costs and improve operating efficiency and quality and effectively address the demands of an increasingly regulated global environment and the evolving trade environment.
Second-quarter 2026 Form 10-Q, business environment: competition and innovation requirements · Filed 21/07/2026
Rales, Chairman of the Executive Committee and co-founder of the Company, were each granted restricted stock units with respect to 500,000 shares of the Company’s common stock (the “Founder RSUs”) as well as awards of stock options.
October 13, 2026 Form 8-K: August 4 founder RSU and option grants · Filed 13/10/2026
Steven and Mitchell Rales waived their right to the Founder RSUs for no consideration.
October 13, 2026 Form 8-K: founder RSU waiver disclosed for October 9 · Filed 13/10/2026
